[go: up one dir, main page]

MX2016009458A - Solucion alcoholica estable de alprostadilo. - Google Patents

Solucion alcoholica estable de alprostadilo.

Info

Publication number
MX2016009458A
MX2016009458A MX2016009458A MX2016009458A MX2016009458A MX 2016009458 A MX2016009458 A MX 2016009458A MX 2016009458 A MX2016009458 A MX 2016009458A MX 2016009458 A MX2016009458 A MX 2016009458A MX 2016009458 A MX2016009458 A MX 2016009458A
Authority
MX
Mexico
Prior art keywords
alprostadil
alcoholic solution
stable alcoholic
acid
active substance
Prior art date
Application number
MX2016009458A
Other languages
English (en)
Other versions
MX369244B (es
Inventor
HÄUSLER Franz
Scheidl Helmut
Wagner Daniel
Original Assignee
Gebro Holding Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gebro Holding Gmbh filed Critical Gebro Holding Gmbh
Publication of MX2016009458A publication Critical patent/MX2016009458A/es
Publication of MX369244B publication Critical patent/MX369244B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01M—PROCESSES OR MEANS, e.g. BATTERIES, FOR THE DIRECT CONVERSION OF CHEMICAL ENERGY INTO ELECTRICAL ENERGY
    • H01M10/00—Secondary cells; Manufacture thereof
    • H01M10/42—Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
    • H01M10/425—Structural combination with electronic components, e.g. electronic circuits integrated to the outside of the casing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Manufacturing & Machinery (AREA)
  • Electrochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica líquida, en particular como concentrado para la producción de una solución de infusión, conteniendo alprostadilo como principio activo, disuelto en un solvente no acuoso, conteniendo al menos un ácido, respectivamente una sustancia que actúa como ácido respectivamente como donante de protones, como estabilizador para el principio activo.
MX2016009458A 2014-01-30 2015-01-29 Solucion alcoholica estable de alprostadilo. MX369244B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA50063/2014A AT515356B1 (de) 2014-01-30 2014-01-30 Stabile alkoholische Lösung von Alprostadil
PCT/AT2015/050029 WO2015113094A1 (de) 2014-01-30 2015-01-29 Stabile alkoholische lösung von alprostadil

Publications (2)

Publication Number Publication Date
MX2016009458A true MX2016009458A (es) 2017-04-25
MX369244B MX369244B (es) 2019-11-01

Family

ID=53432896

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009458A MX369244B (es) 2014-01-30 2015-01-29 Solucion alcoholica estable de alprostadilo.

Country Status (7)

Country Link
EP (2) EP3099330B1 (es)
JP (1) JP2017507172A (es)
AT (1) AT515356B1 (es)
BR (1) BR112016016469B1 (es)
MX (1) MX369244B (es)
RU (1) RU2016135034A (es)
WO (1) WO2015113094A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2695068C1 (ru) * 2018-06-26 2019-07-19 Общество с ограниченной ответственностью "Гурус БиоФарм" Средство для лечения хронических облитерирующих заболеваний периферических сосудов на основе простагландина
EE05864B1 (et) * 2021-12-22 2024-02-15 Aktsiaselts Kevelt 3-hüdroksütsüklopentoonitsüklit sisaldava ühendi kompositsioon ja meetod selle stabiliseerimiseks

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927197A (en) * 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
JPS6019734B2 (ja) * 1977-05-12 1985-05-17 三共株式会社 安定なプロスタグランジンｅ類製剤の製法
ZA831186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
JPH0737389B2 (ja) * 1989-08-29 1995-04-26 久光製薬株式会社 プロスタグランジンｅ１含有の軟膏剤
KR100453803B1 (ko) 1999-07-29 2004-10-20 환인제약 주식회사 알프로스타딜 함유 외용제 조성물
UA78432C2 (uk) * 2005-08-09 2007-03-15 Закрите Акціонерне Товариство Науково-Виробничий Центр "Борщагівський Хіміко-Фармацевтичний Завод" Засіб для лікування ішемічних та гнійно-некротичних уражень нижніх кінцівок при діабетичних ангіопатіях, який містить алпростадил
JP5582635B2 (ja) * 2008-01-24 2014-09-03 テクノガード株式会社 プロスタグランジン含有脂肪乳剤およびその製造方法
CN103458929A (zh) * 2011-03-31 2013-12-18 富士胶片株式会社 含有前列腺素的脂肪乳剂
CN102351767B (zh) * 2011-09-20 2013-03-06 海南美兰史克制药有限公司 一种前列地尔化合物及其制法
CN102688203A (zh) 2012-06-06 2012-09-26 杭州澳亚生物技术有限公司 一种前列地尔冻干粉针剂及其制备方法
CN103110579B (zh) * 2013-02-20 2014-12-10 北京德立福瑞医药科技有限公司 前列地尔注射剂

Also Published As

Publication number Publication date
BR112016016469A8 (pt) 2018-01-30
RU2016135034A (ru) 2018-03-01
JP2017507172A (ja) 2017-03-16
AT515356A1 (de) 2015-08-15
RU2016135034A3 (es) 2018-05-11
MX369244B (es) 2019-11-01
BR112016016469B1 (pt) 2021-09-28
BR112016016469A2 (pt) 2017-08-08
WO2015113094A1 (de) 2015-08-06
EP3395367A1 (de) 2018-10-31
AT515356B1 (de) 2015-11-15
EP3099330B1 (de) 2018-03-14
EP3099330A1 (de) 2016-12-07

Similar Documents

Publication Publication Date Title
SG10201806539XA (en) Liquid protein formulations containing ionic liquids
NZ704584A (en) Liquid stable virus vaccines
PH12017500838B1 (en) Solution comprising nicotine in unprotonated form and protonated form
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
SG10201902915VA (en) Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
BR112014032990A2 (pt) seringa
PH12015500115B1 (en) Glucagon analogues
PH12018500690A1 (en) Novel insulin analogs and use thereof
PH12016500720A1 (en) Stable formulation of insulin glulisine
MY184381A (en) Stable formulations of lipids and liposomes
MX384877B (es) Composiciones de éster de colina de ácido lipoico y métodos de uso.
UA115373C2 (uk) Стабільний рідкий склад amg 416 (велкалсетиду)
EA201691741A1 (ru) Фармацевтическая композиция
MX366953B (es) Composición farmacéutica que no contiene antioxidantes y método de preparación de la misma.
PH12015502571A1 (en) Agrochemical formulations
EA201791290A1 (ru) Жидкая ингибирующая композиция, способ ее приготовления и применение для контроля коррозии в тяжелом солевом растворе
MX2016009458A (es) Solucion alcoholica estable de alprostadilo.
MX2018001041A (es) Concentrado que contiene alprostadil.
MX2016013979A (es) Nuevas vias de administracion de insulina, analogos de insulina o derivados de insulina.
IN2013MU03613A (es)
MX2018001042A (es) Concentrado que contiene alprostadil.
HK1226323A1 (en) Liquid protein formulations containing ionic liquids
HK1226310A1 (en) Liquid protein formulations containing water soluble organic dyes
MY180547A (en) An acid treatment fluid and a process for synthesis of protonic ionic liquid

Legal Events

Date Code Title Description
FG Grant or registration